Dharmacon

News Dharmacon

• Global Market for DNA Oligos Tops $700 Million Annually

  According to the findings of a new report from BioInformatics, LLC, total spending by research scientists on synthetic DNA oligonucleotides (oligos) is over US$700 million annually. In the last decade, the demand for high quality oligonucleotides has risen with the focus on microarray technologies a more

• "RNAi Global" Accelerate Biomedical Discovery Using Genome-Wide siRNA Screening

  The Genome-Wide RNAi Global Initiative (RNAi Global), an alliance of Dharmacon, Inc. and leading international research centers pioneering the use of whole-genome RNAi screening, today announced the addition of new members from Harvard Medical School, Stanford Medical School and the VU University Me more

• Dharmacon and amaxa collaborate to improve siRNA delivery into cells

  Dharmacon, Inc., a business unit of the Fisher Biosciences group, and amaxa announced an agreement to co-promote data generated using Dharmacon's siRNA libraries with amaxa's Nucleofector® technology. Despite the rapid advance of RNAi gene silencing for drug discovery and development, some research more

White papers Dharmacon

• siRNA Silencing of Lamin A and Quantification of the Knockdown Effect via qPCR
  

  Lamins are structural proteins which form a thin fibrous layer called the nuclear lamina. Currently, three types of lamins are known in mammalian cells: lamin A, B, and C. Lamins may be involved in DNA replication, chromatin organization, differentiation, nuclear structural support, nuclear envelope reassembly, and several other processes. Mutations of lamin A can cause muscular dystrophy, dilated cardiomyopathy, familiar partial lipodystrophy [3], and other disorders. For the detailed analysis of the different functions of this more than 70 kDa large protein, the expression should be blocked. more

Market studies Dharmacon

• Alcon, Inc. (ACL) - Product Pipeline Analysis

  Alcon, Inc. (ACL) - Product Pipeline Analysis Summary Alcon, Inc. (Alcon) is one of the leading eye care providers in the world. It is principally engaged in the development, manufacture and marketing of pharmaceuticals, surgical equipment and devices, contacts lens care solutions and other vision more

• RNAi for Therapeutic Applications: Market Prospects 2011-2021

  How will the RNA interference (RNAi) therapies market develop this decade? Our new report shows you that emerging market's revenue potential from 2011 to 2021. You will see the commercial prospects for RNAi-based therapeutics. We aim to save you time and aid your decisions through our research, dat more

Websites Dharmacon